LivaNova PLC (NASDAQ:LIVN) Stake Boosted by Royal Bank of Canada

Royal Bank of Canada increased its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 361,356 shares of the company's stock after buying an additional 26,790 shares during the quarter. Royal Bank of Canada owned about 0.67% of LivaNova worth $16,733,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after buying an additional 265,291 shares in the last quarter. Capital Research Global Investors raised its stake in shares of LivaNova by 19.1% in the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after acquiring an additional 258,730 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after acquiring an additional 107,693 shares in the last quarter. Redmile Group LLC boosted its position in LivaNova by 19.3% during the 4th quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock worth $48,326,000 after purchasing an additional 168,500 shares during the period. Finally, Nuveen Asset Management LLC boosted its position in LivaNova by 0.6% during the 4th quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company's stock worth $38,132,000 after purchasing an additional 5,080 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. The Goldman Sachs Group reduced their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Stifel Nicolaus decreased their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Barclays lowered their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a research report on Tuesday, May 20th. Finally, Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $59.29.

LivaNova Stock Up 0.0%

Shares of NASDAQ:LIVN traded up $0.01 during midday trading on Friday, reaching $43.18. The company had a trading volume of 120,668 shares, compared to its average volume of 650,756. The stock has a market capitalization of $2.35 billion, a P/E ratio of 103.06 and a beta of 0.84. The stock's fifty day moving average price is $38.98 and its 200-day moving average price is $44.41. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a one year low of $32.48 and a one year high of $61.94.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.